Giuseppe
Emeritus
[Source: Eurosurveillance, full page: (LINK). Abstract, edited.]
Eurosurveillance, Volume 19, Issue 9, 06 March 2014 / Rapid communications
Influenza vaccine effectiveness in Spain 2013/14: subtype-specific early estimates using the cycEVA study
S Jim?nez-Jorge <SUP>1</SUP><SUP>,2</SUP>, F Pozo<SUP>3</SUP>, S de Mateo<SUP>1</SUP><SUP>,2</SUP>, C Delgado-Sanz<SUP>1</SUP><SUP>,2</SUP>, I Casas<SUP>3</SUP>, M Garc?a-Cenoz<SUP>2</SUP><SUP>,4</SUP>, J Castilla<SUP>2</SUP><SUP>,4</SUP>, R Sancho<SUP>2</SUP><SUP>,5</SUP>, L Etxebarriarteun-Aranzabal<SUP>6</SUP>, C Quinones<SUP>7</SUP>, E Mart?nez<SUP>7</SUP>, T Vega<SUP>8</SUP>, A Garcia<SUP>8</SUP>, J Gim?nez<SUP>9</SUP>, J M Vanrell<SUP>9</SUP>, D Castrillejo<SUP>10</SUP>, A Larrauri<SUP>1</SUP><SUP>,2</SUP>, on behalf of the Spanish Influenza Sentinel Surveillance System (SISS)<SUP>11</SUP>
<SUP></SUP>
<SUP>1</SUP>National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain - 2 CIBER Epidemiolog?a y Salud P?blica (CIBERESP), Institute of Health Carlos III, Madrid, Spain - 3 National Centre for Microbiology, National Influenza Reference Laboratory, WHO National Influenza Centre, Institute of Health Carlos III, Madrid, Spain - 4 Instituto de Salud P?blica de Navarra, Pamplona, Spain - 5 Direcci?n de Salud P?blica y Adicciones de Gipuzkoa, Pa?s Vasco, Spain - 6 Subdirecci?n de Salud P?blica y Adicciones de Araba/?lava, Pa?s Vasco, Spain - 7 Servicio de Epidemiolog?a y Prevenci?n Sanitaria, Direcci?n General de Salud P?blica y Consumo de La Rioja, La Rioja, Spain - 8 Direcci?n General de Salud P?blica, Consejer?a de Sanidad de Castilla y Le?n, Castilla y Le?n, Spain - 9 Servicio de Epidemiolog?a, Direcci?n General de Salut P?blica, Baleares, Spain - 10 Servicio de Epidemiolog?a, Direcci?n General de Sanidad y Consumo, Consejer?a de Bienestar Social y Sanidad, Ciudad Aut?noma de Melilla, Melilla, Spain - 11 The members are listed at the end of the article
______
Citation style for this article: Jim?nez-Jorge S, Pozo F, de Mateo S, Delgado-Sanz C, Casas I, Garc?a-Cenoz M, Castilla J, Sancho R, Etxebarriarteun-Aranzabal L, Quinones C, Mart?nez E, Vega T, Garcia A, Gim?nez J, Vanrell JM, Castrillejo D, Larrauri A, on behalf of the Spanish Influenza Sentinel Surveillance System (SISS). Influenza vaccine effectiveness in Spain 2013/14: subtype-specific early estimates using the cycEVA study. Euro Surveill. 2014;19(9)
ii=20727. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20727
Date of submission: 14 February 2014
______
Adjusted early estimates of the 2013/14 influenza vaccine effectiveness (VE) in Spain for all age groups was 35% (95% CI: −9 to 62), 33% (95% CI: −33 to 67) and 28% (95% CI: −33 to 61) against any influenza virus type, A(H1N1)pdm09 and A(H3N2) viruses, respectively. For the population targeted for vaccination, the adjusted VE was 44% (95% CI: −11 to 72), 36% (95% CI: −64 to 75) and 42% (95% CI: −29 to 74), respectively. These preliminary results in Spain suggest a suboptimal protective effect of the vaccine against circulating influenza viruses.
-
--------
Eurosurveillance, Volume 19, Issue 9, 06 March 2014 / Rapid communications
Influenza vaccine effectiveness in Spain 2013/14: subtype-specific early estimates using the cycEVA study
S Jim?nez-Jorge <SUP>1</SUP><SUP>,2</SUP>, F Pozo<SUP>3</SUP>, S de Mateo<SUP>1</SUP><SUP>,2</SUP>, C Delgado-Sanz<SUP>1</SUP><SUP>,2</SUP>, I Casas<SUP>3</SUP>, M Garc?a-Cenoz<SUP>2</SUP><SUP>,4</SUP>, J Castilla<SUP>2</SUP><SUP>,4</SUP>, R Sancho<SUP>2</SUP><SUP>,5</SUP>, L Etxebarriarteun-Aranzabal<SUP>6</SUP>, C Quinones<SUP>7</SUP>, E Mart?nez<SUP>7</SUP>, T Vega<SUP>8</SUP>, A Garcia<SUP>8</SUP>, J Gim?nez<SUP>9</SUP>, J M Vanrell<SUP>9</SUP>, D Castrillejo<SUP>10</SUP>, A Larrauri<SUP>1</SUP><SUP>,2</SUP>, on behalf of the Spanish Influenza Sentinel Surveillance System (SISS)<SUP>11</SUP>
<SUP></SUP>
<SUP>1</SUP>National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain - 2 CIBER Epidemiolog?a y Salud P?blica (CIBERESP), Institute of Health Carlos III, Madrid, Spain - 3 National Centre for Microbiology, National Influenza Reference Laboratory, WHO National Influenza Centre, Institute of Health Carlos III, Madrid, Spain - 4 Instituto de Salud P?blica de Navarra, Pamplona, Spain - 5 Direcci?n de Salud P?blica y Adicciones de Gipuzkoa, Pa?s Vasco, Spain - 6 Subdirecci?n de Salud P?blica y Adicciones de Araba/?lava, Pa?s Vasco, Spain - 7 Servicio de Epidemiolog?a y Prevenci?n Sanitaria, Direcci?n General de Salud P?blica y Consumo de La Rioja, La Rioja, Spain - 8 Direcci?n General de Salud P?blica, Consejer?a de Sanidad de Castilla y Le?n, Castilla y Le?n, Spain - 9 Servicio de Epidemiolog?a, Direcci?n General de Salut P?blica, Baleares, Spain - 10 Servicio de Epidemiolog?a, Direcci?n General de Sanidad y Consumo, Consejer?a de Bienestar Social y Sanidad, Ciudad Aut?noma de Melilla, Melilla, Spain - 11 The members are listed at the end of the article
______
Citation style for this article: Jim?nez-Jorge S, Pozo F, de Mateo S, Delgado-Sanz C, Casas I, Garc?a-Cenoz M, Castilla J, Sancho R, Etxebarriarteun-Aranzabal L, Quinones C, Mart?nez E, Vega T, Garcia A, Gim?nez J, Vanrell JM, Castrillejo D, Larrauri A, on behalf of the Spanish Influenza Sentinel Surveillance System (SISS). Influenza vaccine effectiveness in Spain 2013/14: subtype-specific early estimates using the cycEVA study. Euro Surveill. 2014;19(9)
ii=20727. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20727 Date of submission: 14 February 2014
______
Adjusted early estimates of the 2013/14 influenza vaccine effectiveness (VE) in Spain for all age groups was 35% (95% CI: −9 to 62), 33% (95% CI: −33 to 67) and 28% (95% CI: −33 to 61) against any influenza virus type, A(H1N1)pdm09 and A(H3N2) viruses, respectively. For the population targeted for vaccination, the adjusted VE was 44% (95% CI: −11 to 72), 36% (95% CI: −64 to 75) and 42% (95% CI: −29 to 74), respectively. These preliminary results in Spain suggest a suboptimal protective effect of the vaccine against circulating influenza viruses.
-
--------